Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | GBA1 | P04062 | 12/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11318961 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL94371 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL21959579 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL19501713 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL15944228 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL24675720 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL19663777 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL15203072 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL25818947 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL25516156 | 0.98 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011049232-A1 | DIARYLTRIAZOLE DERIVATIVE AS INSECTICIDE, MITICIDE, NEMATICIDE OR SOIL PESTICIDE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-04-28 | — | — | WO | claimed |
| CN-113614222-A | Blood brain barrier in vitro | 麻省理工学院 | 2021-11-05 | — | — | CN | disclosed |
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2008049994-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2008-05-02 | — | — | WO | disclosed |
| CN-1938286-A | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK & CO INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1501505-B1 | USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H- 1,2,4 -TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SIGMA TAU IND FARMACEUTI (IT) | 2006-01-18 | — | — | EP | disclosed |
| US-20050026980-A1 | Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-02-03 | — | — | US | disclosed |
| EP-1501505-A1 | USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H- 1,2,4 -T RIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-02-02 | — | — | EP | disclosed |
| US-6797722-B2 | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-28 | — | — | US | disclosed |
| WO-2003092681-A1 | USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H-[1,2,4]-TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-11-13 | — | — | WO | disclosed |
| US-20030207931-A1 | USE OF 3-(2-ETHYLPHENYL)-5-(3-METHOXYPHENYL)-1H-1,2,4-TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-11-06 | — | — | US | disclosed |
| CN-1076728-C | Derivative of 2-aryl imidazo [2,1-a] isoquinoline and its use | UNIV ZHEJIANG (CN) | 2001-12-26 | — | — | CN | disclosed |
| CN-1228431-A | Derivative of 2-aryl imidazo [2,1-a] isoquinoline and its use | UNIV ZHEJIANG (CN) | 1999-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | HRH4 4179/4885HRH3 4144/4885GBA1 2917/4885 |
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | TP53, TP53BP1, MDM2 | HRH4 4471/4885HRH3 4541/4885GBA1 2460/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885GBA1 280/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | HRH4 4334/4885HRH3 3879/4885GBA1 2752/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | HRH4 2338/4885HRH3 1911/4885GBA1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.